IRCT20080901001165N46RecruitingPhase 3
Investigating the efficacy and safety of Umifenovir in controlling the symptoms of patients with COVID-19
Center for Progress and Development of Iran0 sites200 target enrollmentStarted: TBDLast updated:
Trial Snapshot
- Phase
- Phase 3
- Status
- Recruiting
- Sponsor
- Enrollment
- 200
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 years to no limit (—)
- Sex
- All
Inclusion Criteria
- •age >18 years
- •The patient have written consciously and freely consent to participate in the study.
- •Confirmed diagnosis of COVID-19, with Laboratory (RT-PCR) confirmation.
- •Confirmed diagnosis of COVID-19, with lung CT-Scan result, which is typical for COVID-19 pulmonary involvement.
- •O2 saturation at rest in ambient air =93%
Exclusion Criteria
- •Concurrent treatment with other agents with actual or possible direct acting antiviral activity against SARS-CoV-2.
- •Participation in any other clinical trial of an experimental treatment for COVID-19
- •Pregnant or breastfeeding;
- •Hypersensitivity reaction history with Umifenovir.
- •patient with critical stage of disease (respiratory failure, sock, multi organ dysfunction)
- •patient with at least one of these disease as past medical history: congenital heart disease, Congestive heart failure, coronary artery disease, severe heart rhythm disorders, serious neurological disease including stroke, epilepsy, mental retardation, spinal cord injury.
- •Patients with immunodeficiency, including malignancies, HIV, organ transplants, receiving immunosuppressive drugs in the last previous 3 months.
Investigators
Similar Trials
Completed
Phase 3
mifenovir effectiveness in the treatment of COVID-19IRCT20200322046833N1Center for Progress and Development of Iran100
Completed
Phase 3
Effect of Umifenovir in treatment of covid-19IRCT20200523047550N1Tehran University of Medical Sciences50
Recruiting
Phase 3
Evaluating the effects of Umifenovir (Arbidol) in COVID-19IRCT20151227025726N15Shahid Beheshti University of Medical Sciences100
Recruiting
Phase 4
The study to evaluate the efficacy and safety of using Platelet-rich plasma combined with hyaluronic acid for treating neck rejuvenation in Thailand.HealthyPlatelet-rich plasma, neck rejuvenation, hyaluronic acidTCTR20230212003ASTRACO MEDICAL NETWORKS LTD.32
Completed
Phase 4
The study to evaluate the efficacy and safety of using hyaluronic acid filler to enhance lips in Thailand, Pilot studyips volumn lossHyaluronic acid, Filler, LipsTCTR20220528006Dermatologic Surgery, Dermatology department, Siriraj hospital, Thailand20